Semen News and Research

RSS

Semen is an organic fluid, also known as seminal fluid, that usually contains spermatozoa. It is secreted by the gonads (sexual glands) and other sexual organs of male or hermaphroditic animals and can fertilize female ova. The process of discharge is called ejaculation.

Walnuts provide key nutrients that may be essential in male reproductive health

Research published in the recent issue of Biology of Reproduction Papers-in-Press reports that 75 grams (approximately 2.5 ounces) of walnuts consumed per day improved sperm vitality, motility, and morphology (normal forms) in a group of healthy young men between 21-35 years of age.

17 Aug 2012

Smoking is bad for your sperm

In men with varicocele, smoking alters semen quality and sperm function as well as inducing seminal oxidative stress, report researchers.

13 Aug 2012

AIDS medical textbook designed specifically for patients and doctors in resource-poor regions

Warner C. Greene, MD, who directs virology and immunology research at the Gladstone Institutes, has joined with other global AIDS experts to release a locally affordable version of the world's leading AIDS medical textbook. Designed specifically for regions that today are hardest hit by the disease, this new text is the latest weapon in a growing arsenal aimed at curbing the spread of HIV/AIDS worldwide.

24 Jul 2012

Arsenic exposure impairs semen quality

Environmental exposure to arsenic significantly reduces semen quality in Chinese men, research shows.

18 Jul 2012

Smoking of fathers before conception can damage genetic information of their offspring

As you decide what to get dad for Father's Day, you might want to consider what he gave you when you were conceived. If he smoked, your genes are likely damaged, and your odds for cancers and other diseases throughout your life could be increased. A new research report appearing online in the FASEB Journal, scientists show for the first time in humans that men who smoke before conception can damage the genetic information of their offspring.

23 Jun 2012

Breakthrough in understanding the causes of unexplained male infertility

The diagnosis of male fertility is usually performed through the observation of the sperm in the microscope. However, a normal quality semen does not guarantee an adequate fertility. In fact, there is a considerable proportion of cases of unexplained infertility and data suggest that abnormal sperm function may have a genetic or molecular origin.

24 May 2012

Linkam Scientific temperature controlled warm stages chosen for sperm motility in human fertility testing

Market leaders in temperature controlled microscopy, Linkam Scientific Instruments, have been chosen by an NHS Fertility clinic as suppliers of a controlled warm stage to perform routine semen analysis at body temperature.

From Linkam Scientific Instruments 16 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

High rates of birth defects associated with an artificial reproductive technology: Study

A new study has shown that one of the most popular forms of IVF could double the risk of birth defects.

8 May 2012

Gladstone researcher wins 2012 Alumni Achievement Award from WUSTL

Warner C. Greene, MD, PhD-who directs virology and immunology research at the Gladstone Institutes-has won the 2012 Alumni Achievement Award from the Washington University School of Medicine in St. Louis.

26 Apr 2012

New test accurately detects aggressive prostate cancer

One in six men will be diagnosed with prostate cancer during his lifetime, the second leading cause of death among men in the United States. It's a serious problem and current diagnostic tests aren't very specific. But a research team at the University of Central Florida NanoScience Technology Center has found a more accurate test that not only determines whether a patient has prostate cancer, but also how aggressive it is.

26 Apr 2012

HAART does not completely suppress HIV in sexually active MSM

Researchers from Boston University School of Medicine (BUSM) and Fenway Health have found that highly active antiretroviral therapy (HAART) does not completely suppress HIV in the semen of sexually active HIV-infected men who have sex with men.

28 Mar 2012

Studies provide global perspective on condom use problems and errors

Problems with the correct use of the male condom, such as not wearing a condom throughout sex or putting it on upside down, are common in the U.S. and have become a major concern of public health officials. New research shows that countries around the world are facing similar challenges.

23 Feb 2012

Cooked tomatoes could help in prostate cancer: Study

Scientists have discovered the nutrient, lycopene, which is found in cooked tomatoes, can slow the growth and even kill the cancer cells. Dr Mridula Chopra and colleagues at the University of Portsmouth found that lycopene, which gives tomatoes their red color, intercepts the cancer's ability to make the connections it needs to attach to a healthy blood supply.

1 Feb 2012

Lycopene can kill prostate cancer cells

A nutrient in cooked tomatoes has been shown in laboratory studies to slow the growth of or even kill prostate cancer cells.

31 Jan 2012

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011